Brian Kabot bought $1,379 of MNTS
director at Momentus Inc.. 250 shares at an average of $5.52, traded May 20, 2026, filed May 22, 2026.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- +3Relative to holdingsHoldings up 6%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001786113-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 20, 2026 | POpen-market purchase Class A Common Stock | +250 | $5.52 | $1,379 | 4,708 | May 22, 2026 |
Related signals
Other insiders at Momentus Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Momentus Inc. | Chris Hadfield director | $14k 2,000 shares | +133% | |
| 33Weak | Momentus Inc. | Brian Kabot director | $9,999 1,850 shares | +128% | |
| 31Weak | Momentus Inc. | Brian Kabot director | $1,404 250 shares | +6% | |
| 31Weak | Momentus Inc. | Chris Hadfield director | $7,980 1,500 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.